Preview Mode Links will not work in preview mode

This Week in Cardiology

Apr 29, 2022

Aspirin for primary prevention, time-restricted feeding, renal denervation, and a potential new obesity drug are the topics John Mandrola, MD, covers in this week’s podcast.

This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I – ASA for Primary Prevention:

- USPSTF Final Recommendation on Aspirin for Primary CV Prevention

- Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement

- Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly

- Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

II – Time Restricted Feeding

- Is There a Benefit to Fasting Plus Calorie Counting?

- Calorie Restriction with or without Time-Restricted Eating in Weight Loss

- Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity. The TREAT Randomized Clinical Trial

III – Renal Denervation

- Renal Denervation BP Benefits Remain at 3 Years: SPYRAL HTN-ON

- Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial

IV – Tirzepatide for Obesity

- Tirzepatide Excites in Obesity Now Too, Says Lilly

- Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD

Questions or feedback, please contact